Fortrea published an early-stage trial showing that a single-dose experimental gene-editing therapy reduced bad cholesterol and triglycerides in patients for over a year.
Published
Signal category
Research & Knowledge
Quote
“An early-stage trial reported that a single-dose experimental gene-editing therapy reduced 'bad' cholesterol and triglycerides in patients for over a year.”
— Delphine Deschepper|Fortrea team
Company
Fortrea
Bringing life-changing benefits to patients faster
- Industry
- Biotechnology Research
- Location
- Research Triangle Park, US
- Company size
- 11,455 employees
Fortrea (Nasdaq: FTRE) is a leading global clinical research organization (CRO) dedicated to providing innovative clinical development solutions to the life sciences industry. With over 30 years of clinical research experience, Fortrea has evolved from Covance and Labcorp into a pureplay CRO built for biotech, biopharma, medical device and diagnostic innovators. Fortrea collaborates with both emerging and established companies to deliver agile, fit-for-purpose full service (FSO), functional service (FSP) and hybrid solutions. Fortrea provides comprehensive Phase I-IV clinical trial management, clinical pharmacology, and consulting services, backed by deep experience in more than 20 therapeutic areas. Operating in approximately 100 countries, our diverse and talented team brings scientific rigor, operational excellence, and a strong investigator site network to every trial. By combining the best of our legacy experience with forward-thinking innovation, Fortrea brings predictability to clinical trial execution and helps transform aspirations into outcomes. Together, exceptional is possible. Learn more at Fortrea.com